Monday's ETF Winners & Losers

Funds tracking biotech and energy are rising.
Author:
Publish date:

Biotech-related exchange-traded funds were among the day's top performers, helped by an 18% jump in shares of

MedImmune

(MEDI)

.

Earlier, the company said it will be acquired by

AstraZeneca

(AZN) - Get Report

in an arrangement worth more than $15 billion.

The

SPDR S&P Biotech

(XBI) - Get Report

ETF was gaining $1.02, or 2%, to $52.96. The

HealthShares Emerging Cancer

(HHJ)

was higher by 47 cents, or 1.8%, to $26.94. The

First Trust Amex Biotechnology Index

(FBT) - Get Report

tacked on 38 cents, or 1.5%, to $26.01. The

iShares Nasdaq Biotechnology

(IBB) - Get Report

ETF was recently up $1.01, or 1.2%, to $82.47.

Bundled securities tracking the energy sector were also among the winners of the day thanks to a gain in oil prices. The front-month June crude contract was recently adding $1.15 to $65.26 a barrel.

The

iPath Goldman Sachs Crude Oil Index

(OIL) - Get Report

was rising 75 cents, or 2.1%, to $37.30. The

United States Oil

(USO) - Get Report

ETF gained 92 cents, or 1.8%, to $50.97. The

PowerShares DB Energy

(DBE) - Get Report

ETF was climbing 44 cents, or 1.6%, to $27.87.

On the other hand, housing-related ETFs were the worst performers of the session. Among individual housing names,

D.R. Horton

(DHI) - Get Report

slid 3.7%,

Lennar

(LEN) - Get Report

was sinking 2.9%,

Toll Brothers

(TOL) - Get Report

slumped 2.2%, and

Hovnanian

(HOV) - Get Report

was down 1.8%.

The

iShares Dow Jones U.S. Home Construction

(ITB) - Get Report

ETF was recently down 69 cents, or 1.9%, at $36.37. The

SPDR Homebuilders

(XHB) - Get Report

ETF was losing 60 cents, or 1.7%, to $34.49.